NewAmsterdam to receive a total deal value of ~$1.05B incl. $120.90M up front, $28.91M in R&D funding & will be eligible to receive ~$907.33M in clinical, regulatory & commercial milestones along with royalties on net sales of obicetrapib in EU. The companies will work together to gain the product’s regulatory approval
NewAmsterdam to get all rights to commercialize obicetrapib globally if approved & obtain rights to develop the forms of obicetrapib for other diseases incl. AD. The collaboration combines NewAmsterdam’s obicetrapib with Menarini’s CV disease & regional expertise
NewAmsterdam will lead the clinical development of obicetrapib. Menarini will be responsible for all commercialization activities in the licensed territory
Ref: PRNewswire | Image: NewAmsterdam Pharma
